Progress in primary pulmonary hypertension (PPH) and familial primary pulmonary hypertension (FPPH) has led to the development of two general testable hypotheses. 1) Vasoactive mediators in PPH/FPPH will elucidate the pathogenesis of the vascular lesions and 2) restriction fragment length polymorphisms may yield insight into the location and type of genetic defect.
Showing the most recent 10 out of 515 publications